| Title |
Treatment cost of narcolepsy with cataplexy in Central Europe
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, November 2016
|
| DOI | 10.2147/tcrm.s119888 |
| Pubmed ID | |
| Authors |
Petra Maresova, Michal Novotny, Blanka Klímová, Kamil Kuča |
| Abstract |
Narcolepsy is a lifelong, rare neurological sleep disorder characterized by chronic, excessive attacks of daytime sleepiness. This disease is often extremely incapacitating, interfering with every aspect of life, in work and social settings. The purpose of this study is to specify the treatment costs of patients in Central Europe (Czech Republic), while the attention is mainly paid to the drugs that were fully or partially covered by public health insurance. Furthermore, concomitant therapy is also evaluated, since it incurs a certain financial burden for patients and their family members. On the basis of the calculated costs, impact on the public budget is evaluated. This study monitors the direct costs of the drugs for 13 patients, who represent ~1.3% of the total number of diagnosed patients in the Czech Republic, and evaluates the costs associated with their treatment during the period from January 9, 2011 to April 23, 2013. Most of the treatment costs (~80%) were covered by publicly available sources. This finding is also true for the concomitant therapy of comorbidities. Additional payments for the drugs constitute about 20% of the total costs. |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 17% |
| Researcher | 3 | 13% |
| Student > Postgraduate | 2 | 8% |
| Student > Master | 2 | 8% |
| Librarian | 1 | 4% |
| Other | 3 | 13% |
| Unknown | 9 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Economics, Econometrics and Finance | 3 | 13% |
| Social Sciences | 3 | 13% |
| Medicine and Dentistry | 3 | 13% |
| Psychology | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 11 | 46% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 February 2024.
All research outputs
#8,614,141
of 25,576,275 outputs
Outputs from Therapeutics and Clinical Risk Management
#462
of 1,324 outputs
Outputs of similar age
#119,082
of 318,349 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#9
of 24 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,324 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 318,349 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.